aap submits CE marking application for its innovative antibacterial silver coating technology
(Thomson Reuters ONE) -
aap Implantate AG /
aap submits CE marking application for its innovative antibacterial silver
coating technology
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
aap Implantate AG (XETRA: AAQ.DE) announces that the design dossier for the
performance of a CE conformity assessment procedure for the antibacterial silver
coating technology developed by the company was recently submitted to a notified
body leading in the field of medical products. The conformity assessment
procedure will initially be undertaken for a silver-coated LOQTEQ® plate. In
case of a successful conformity assessment, the company plans to extend the
approval to further trauma products.
aap Implantate AG's silver coating technology addresses infection prevention,
which is one of the critical problems in surgery that haven't yet been resolved
adequately. During a procedure medical implants can become colonized by bacteria
from the surrounding area forming a biofilm thereafter which can cause serious
infections later. Both antibiotics and the human immune system have only a very
limited effect against biofilms. It is therefore desirable to combat the biofilm
formation at an early stage. This is where aap Implantate AG's silver coating
technology becomes effective by protecting the implants' surface against
bacterial colonisation. As there are no considerable resistances against silver
the coating also protects against the colonisation by the particular problematic
multiresistant germs.
The unique selling propositions of the silver coating technology developed by
aap Implantate AG have been demonstrated in diverse trials and consist of the
high coating stability as well as the good biocompatibility and effectiveness.
It is furthermore a cost-efficient coating technology due to the relatively
short coating time and the comparatively low capital investment for the required
coating machines.
Overall aap Implantate AG's silver coating technology has a wide range of
applications as a platform technology and can in a next step be used inter alia
in other areas such as cardiology and dentistry or for a variety of medical
instruments.
By submitting the design dossier for the performance of a CE conformity
assessment procedure for the silver coating technology aap Implantate AG makes
important progress regarding its strategic objective to accelerate value-based
innovations.
About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered
in Berlin, Germany. The company develops, manufactures and markets trauma and
biomaterials products for orthopedics. The trauma portfolio includes besides the
innovative anatomical plating system LOQTEQ® a wide range of cannulated screws
as well as standard plates and screws. In the biomaterials business the company
is specialized on bone cements and mixing systems. In German-speaking countries
aap Implantate AG directly sells its trauma products to hospitals, buying
syndicates and hospital groups while it uses a broad network of distributors in
more than 60 countries at the international level. In the biomaterials business
sales are handled via OEM and private label cooperations with several selected
international orthopedic and trauma companies. aap Implantate AG's stock is
listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA:
AAQ.DE). For more information, please visit www.aap.de, or download the
Company's investor relations app from the Apple's App Store or Google Play.
Forward-looking statement
This release may contain forward-looking statements based on current experience,
estimates and projections of the management board and currently available
information. They are not guarantees of future performance. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. Many factors could
cause the actual results, performance or achievements of aap to be materially
different from those that may be expressed or implied by such statements. These
factors include those discussed in aap's public reports. Forward-looking
statements therefore speak only as of the date they are made. aap does not
assume any obligation to update the forward-looking statements contained in this
release or to conform them to future events or developments.
For inquiries please contact: aap Implantate AG, Fabian Franke, Investor
Relations, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke(at)aap.de
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: aap Implantate AG via GlobeNewswire
[HUG#1981358]
Unternehmensinformation / Kurzprofil:
Datum: 26.01.2016 - 14:43 Uhr
Sprache: Deutsch
News-ID 446577
Anzahl Zeichen: 5800
contact information:
Town:
Berlin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 280 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"aap submits CE marking application for its innovative antibacterial silver coating technology"
steht unter der journalistisch-redaktionellen Verantwortung von
aap Implantate AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
